Molecular simulations of aromatase reveal new insights into the mechanism of ligand binding.
CYP19A1, also known as aromatase or estrogen synthetase, is the rate-limiting enzyme in the biosynthesis of estrogens from their corresponding androgens. Several clinically used breast cancer therapies target aromatase. In this work, explicitly solvated all-atom molecular dynamics simulations of aromatase with a model of the lipid bilayer and the transmembrane helix are performed. The dynamics of aromatase and the role of titration of an important amino acid residue involved in aromatization of androgens are investigated via two 250-ns long simulations. One simulation treats the protonated form of the catalytic aspartate 309, which appears more consistent with crystallographic data for the active site, while the simulation of the deprotonated form shows some notable conformational shifts. Ensemble-based computational solvent mapping experiments indicate possible novel druggable binding sites that could be utilized by next-generation inhibitors. In addition, the effects of protonation on the ligand positioning and channel dynamics are investigated using geometrical models that estimate the opening width of critical channels. Significant differences in channel dynamics between the protonated and deprotonated trajectories are exhibited, suggesting that the mechanism for substrate and product entry and the aromatization process may be coupled to a "locking" mechanism and channel opening. Our results may be particularly relevant in the design of novel drugs, which may be useful therapeutic treatments of cancers such as those of the breast and prostate.
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0340, USA.
Jiho
J
Park
Luke
L
Czapla
Rommie E
RE
Amaro
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology; D001141:Aromatase / Q000737:chemistry* / Q000378:metabolism*; D047072:Aromatase Inhibitors / Q000378:metabolism / Q000494:pharmacology; D020134:Catalytic Domain; D015195:Drug Design; D004721:Endoplasmic Reticulum / Q000378:metabolism; D056004:Molecular Dynamics Simulation; D011485:Protein Binding; D011522:Protons
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D011522:Protons; D001141:Aromatase